Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-05-18 16:11:02 ET · period of report 2026-05-14 · accession 0000905148-26-002500 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 16:11 | 2026-05-14 | ACRV | Gamelin Erick | Chief Development Off | F - Tax | $1.92 | -404 | 14.4K | -3% | -$775.68 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-14 | F | D | 404 | $1.92 | 14,408 | D | — | — | (F1) Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. |